Previous 10 | Next 10 |
The definition of penny stocks includes stocks under $5, but for some, that’s too expensive. True penny stocks trading for less than $1 seem to have gained much more attention in the stock market today. Thanks partly to the overall stock market crash this year, many new stocks ar...
3 Trending Penny Stocks to Watch as June Ends Finding trending penny stocks to buy is not easy. Especially when we consider how much is going on in the stock market as of late, trending penny stocks are not easy to come by. However, with the right research on hand, we can find plent...
- Topline results expected in the second half of 2022 - - Rosacea affects about 16 million patients in the U.S. - SAN DIEGO, CA / ACCESSWIRE / June 13, 2022 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA), a clinical-stage biotechnology company focusing on ...
SAN DIEGO, CA / ACCESSWIRE / May 23, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced that Gerry Proehl, Dermata's Chairman, President, and ...
Dermata Therapeutics press release (NASDAQ:DRMA): Q1 GAAP EPS of -$0.33 beats by $0.07. $8.2M in cash and gross proceeds of $5M in April 2022 from a private placement of securities together with existing cash resources, are expected to fund operations into the second quarter of 2023. ...
Dermata completes a $5.0 million private placement financing DMT310 Phase 2 rosacea trial topline results expected in H2 2022 SAN DIEGO, CA / ACCESSWIRE / May 16, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA; DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology com...
SAN DIEGO, CA / ACCESSWIRE / April 25, 2022 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) (NASDAQ:DRMAW) , a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced the closing of its previously anno...
Dermata Therapeutics (NASDAQ:DRMA) has announced a $5M private offering priced at-the-market under Nasdaq rules. The biotech firm entered into a securities purchase agreement with a single institutional investor to purchase ~$5M of its common stock (or pre-funded warrants to purchase common s...
SAN DIEGO, CA / ACCESSWIRE / April 21, 2022 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) and (NASDAQ:DRMAW) , a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced that it has entered into a s...
Gainers: Sunshine Biopharma (SBFM) +181%. Nano-X Imaging (NNOX) +15%. Arcus Biosciences (RCUS) +13%. Cue Biopharma (CUE) +11%. Dermata Therapeutics (DRMA) +6%. Losers: IMARA (IMRA) -35%. GBS (GBS) -15%. Precipio (PRPO) -13%. Cassava Sciences (SAVA) -10%...
News, Short Squeeze, Breakout and More Instantly...
Dermata Therapeutics Inc. Company Name:
DRMA Stock Symbol:
NASDAQ Market:
Dermata Therapeutics Inc. Website:
SAN DIEGO, CA / ACCESSWIRE / May 17, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced the entry into definitive agreement...
- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial enrollment remains on track - - Dermata continues discussions with potential botulinum toxin partners for DMT410 - - Received issuance of Japanese patent for DMT410 for the treatment of hyperhidrosis - SAN...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...